A Case of Antithyroid Drug-Induced Agranulocytosis Pre-Covid 19 Era

Simple item page
dc.contributor.authorSufian K. M. Noor
dc.contributor.author, Mosab Nouraldein Mohammed Hamad
dc.contributor.author, Sarra Osman Bushara
dc.contributor.author, Amel Abdalrhim Sulaiman3
dc.contributor.authorMohamed Adil Yassen Ali4
dc.contributor.author, Remaz Khalid Hassan Ahmed4
dc.contributor.author, Almotasim Mohamed Aabdelmgid Elnaema
dc.contributor.authorSamaher Mozamil Mohamed Abdelrahim
dc.date.accessioned2023-11-23T09:22:29Z
dc.date.available2023-11-23T09:22:29Z
dc.date.issued2020
dc.description.abstractAgranulocytosis is an infrequent and serious side effect of antithyroid drugs characterized by a noticeable reduction in granulocyte and neutrophil count, it usually occurs within the first 2-3 months of treatment. There is a variety of mechanisms by which ATD can induce agranulocytosis, direct drug effects, and immunological mechanisms. We present 33 years old female attended Atbara teaching hospital who has developed agranulocytosis 2 weeks after starting ATD to treat relapsed Graves’ disease. What was unusual about this patient is that symptoms have occurred in a period less than 15 days of starting treatment and with a dose of 45 mg/day. The physician must educate the patient about the possibility of early onset of serious side effects of ATD and to seek medical advice as soon as possible
dc.identifier.urihttps://ds.eaeu.edu.sd/handle/10.58971/435
dc.language.isoother
dc.publisherجامعة الشيخ عبدالله البدري
dc.titleA Case of Antithyroid Drug-Induced Agranulocytosis Pre-Covid 19 Era
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
A-Case-of-Antithyroid-Drug-Induced-Agranulocytosis-Pre-Covid-19-Era.pdf
Size:
240.8 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Thesis